Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight

globenewswire.com
CYTK Mentioned as a key company in the Coronary Artery Disease market and Chronic Heart Failure market reports, indicating its involvement in the cardiovascular therapeutic space. NVO Listed as a key company in the Coronary Artery Disease market and Chronic Heart Failure market reports, highlighting its presence in cardiovascular research and development. BCDA Identified as a key company in both the Coronary Artery Disease market and Chronic Heart Failure market reports, suggesting its role in cardiovascular treatments. AZN Appears as a key company in the Coronary Artery Disease market, Chronic Heart Failure market, and Acute Heart Failure market reports, indicating broad engagement in cardiovascular research. MESO Identified as a key company in both the Coronary Artery Disease market and Chronic Heart Failure market reports, suggesting its focus on regenerative medicine for heart conditions. GEHC Mentioned as a key company in the Coronary Artery Disease Treatment Devices Market report, indicating its role in providing medical devices for CAD treatment. BSX Listed as a key company in the Coronary Artery Disease Treatment Devices Market report, highlighting its contribution to cardiovascular treatment devices. MDT Identified as a key company in the Coronary Artery Disease Treatment Devices Market report, indicating its role in the cardiovascular device sector. ABT Mentioned as a key company in the Coronary Artery Disease Treatment Devices Market report, signifying its presence in the cardiovascular device industry. LIVN Identified as a key company in the Coronary Artery Disease Treatment Devices Market report, suggesting its role in neuromodulation and advanced circulatory support devices. OSCR Mentioned as a key company in the Coronary Artery Disease Treatment Devices Market report, indicating its focus on cardiac monitoring and mapping systems. EL Listed as a key company in the Chronic Heart Failure Market and Acute Heart Failure Market reports, indicating its involvement in cardiovascular drug development. BMY Mentioned as a key company in the Chronic Heart Failure Market and Acute Heart Failure Market reports, indicating its broad engagement in cardiovascular and other therapeutic areas. ARE Mentioned as a key company in the Acute Heart Failure Market report, indicating its involvement in developing treatments for cardiovascular conditions. AVT Identified as a key company in the Acute Heart Failure Market report, indicating its role in the development of cardiovascular therapies. RNTX Identified as a key company in the Advanced Heart Failure Market report, indicating its focus on gene therapy for cardiovascular diseases.

Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight New York, USA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight

The coronary artery disease clinical trial analysis report delivers important insights into ongoing research of 20+ pipeline Coronary Artery Disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Coronary Artery Disease Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for Coronary Artery Disease across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the Coronary Artery Disease domain.

Coronary Artery Disease Clinical Trial Analysis Summary

Request a sample and discover the recent advances in Coronary Artery Disease treatment @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight

What is Coronary Artery Disease?

Coronary Artery Disease (CAD) is a common type of heart disease that occurs when the coronary arteries become narrowed or blocked, primarily due to the buildup of fatty deposits called plaque. This process, known as atherosclerosis, can restrict blood flow and reduce the supply of oxygen to the heart muscle. CAD may develop gradually and can cause symptoms such as chest pain or pressure (angina), shortness of breath, fatigue, and reduced exercise tolerance. In severe cases, complete blockage of a coronary artery can lead to a heart attack. Major risk factors include high cholesterol, high blood pressure, diabetes, smoking, obesity, physical inactivity, and a family history of cardiovascular disease.

Find out more about treatment for Coronary Artery Disease @ Coronary Artery Disease New Treatment

A snapshot of the Pipeline Coronary Artery Disease Drugs mentioned in the report:

Learn more about the Coronary Artery Disease research @ Coronary Artery Disease Clinical Trials

Arunima Dabral, Assistant Project Manager of Consulting and Competitive Intelligence, said that the CAD treatment landscape is evolving with increasing focus on addressing residual cardiovascular risk beyond conventional lipid-lowering and antithrombotic therapies. Emerging approaches targeting Lp(a), inflammation, plaque progression, and thrombosis are expected to expand treatment options for high-risk patients. The growing development of long-acting and genetically targeted therapies may further transform CAD management by enabling more durable risk reduction.

Recent Developments in Coronary Artery Disease Treatment Space

Scope of the Coronary Artery Disease Pipeline Report

Dive deep into rich insights for Coronary Artery Disease cure, visit @ Coronary Artery Disease News

Table of Contents

For further information on the Coronary Artery Disease clinical trials, reach out @ Coronary Artery Disease Medication

Related Reports

Coronary Artery Disease Market

Coronary Artery Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Coronary Artery Disease companies, including Cytokinetics, Novo Nordisk, BioCardia, Cardurion Pharmaceuticals, Bayer, AstraZeneca, Boehringer Ingelheim, Mesoblast, AskBio, and others.

Coronary Artery Disease Treatment Devices Market

Coronary Artery Disease Treatment Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key CHF treatment devices companies, including GE HealthCare, Boston Scientific Corporation, Medtronic, Abbott, Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and others.

Chronic Heart Failure Market

Chronic Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key chronic heart failure companies, including Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, and others.

Acute Heart Failure Market

Acute Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute heart failure companies, including Arena Pharmaceuticals, AstraZeneca, Palatin Technologies, Inc, Boehringer Ingelheim, Eli Lilly and Company, Aventyn, Inc., Corthera, Inc, Idorsia Pharmaceuticals Ltd., The Medicines Company, Bristol-Myers Squibb, Cardioxyl Pharmaceuticals, Inc, Nile Therapeutics, Trevena Inc., Scios, Inc., Novartis, and others.

Advanced Heart Failure Market

Advanced Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced heart failure companies, including Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.